Cancer-focused Array for Malignancies, Tumors

Oxford Gene Technology (OGT) offers the  CytoSure Consortium Cancer +SNP array (4x180k). The array allows the simultaneous detection of copy number variation (CNV) and loss of heterozygosity (LOH), with a SNP resolution that enables reporting of LOH at 10Mb. Focusing on content recommended by an international organization of clinical cytogeneticists, molecular cytogeneticists and molecular pathologists, this targeted array covers over 500 cancer genes and 130 cancer-associated genomic regions for hematological malignancies and solid tumors. The CCMC-approved standardized array design is intended to improve clinical research quality and promotes collaboration and communication between cancer cytogenomics laboratories. Due to the unique design of OGT’s SNP probes, there are no changes to the standard aCGH protocol, no restriction digest is required and any reference sample can be used. This enables the use of matched samples, which is a particular advantage in cancer research, allowing constitutional abnormalities to be filtered out. The array also comes with CytoSure Interpret Software, which delivers reliable and user-friendly data analysis and provides rapid access to meaningful results.

Oxford Gene Technology, +44 (0) 1865 856826, www.ogt.com/cancer.